Detailed clinical, physiological and pathological phenotyping can impact access to disease-modifying treatments in ATTR carriers
Authors:
Open Access
- 24 October 2023
- journal article
- research article
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 95 (6) , 489-499
Abstract
Background: Hereditary transthyretin amyloidosis is a life-threatening autosomal dominant systemic disease due to pathogenicTTRvariants (ATTRv), mostly affecting the peripheral nerves and heart. The disease is characterised by a combination of symptoms, organ involvement and histological amyloid deposition. The available disease-modifying ATTRv treatments (DMTs) are more effective if initiated early. Pathological nerve conduction studies (NCS) results are the cornerstone of large-fibre polyneuropathy diagnosis, but this anomaly occurs late in the disease. We investigated the utility of a multimodal neurological and cardiac evaluation for detecting early disease onset in ATTRv carriers.Methods: We retrospectively analysed a cohort of ATTRv carriers with normal NCS results regardless of symptoms. Multimodal denervation and infiltration evaluations included a clinical questionnaire (Lauria and New York Heart Association (NYHA)) and examination, intra-epidermal nerve fibre density assessment, autonomic assessment based on heart rate variability, Sudoscan, meta-iodo-benzyl-guanidine scintigraphy, cardiac biomarkers, echocardiography, MRI and searches for amyloidosis on skin biopsy and bone scintigraphy.Results: We included 130 ATTRv carriers (40.8% men, age: 43.6±13.5 years), with 18 amyloidogenicTTRgene mutations, the majority of which was the late-onset Val30Met variant (42.3%). Amyloidosis was detected in 16.9% of mutation carriers, including 9 (6.9%) with overt disease (Lauria>2 or NYHA>1) and 13 asymptomatic carriers (10%) with organ involvement (small-fibre neuropathy or cardiomyopathy). Most of these patients received DMT. Abnormal test results of unknown significance were obtained for 105 carriers (80.8%). Investigations were normal in only three carriers (2.3%).Conclusions: Multimodal neurological and cardiac investigation of TTRv carriers is crucial for the early detection of ATTRv amyloidosis and initiation of DMT.Keywords
This publication has 46 references indexed in Scilit:
- Online Registry for Mutations in Hereditary Amyloidosis Including Nomenclature RecommendationsHuman Mutation, 2014
- Small fibre neuropathyCurrent Opinion in Neurology, 2012
- Tafamidis for transthyretin familial amyloid polyneuropathyNeurology, 2012
- Role of Cardiac Magnetic Resonance Imaging in the Detection of Cardiac AmyloidosisJACC: Cardiovascular Imaging, 2010
- Intraepidermal nerve fiber density and its application in sarcoidosisNeurology, 2009
- Heterogeneity of penetrance in familial amyloid polyneuropathy, ATTR Val30Met, in the Swedish populationAmyloid, 2008
- Noninvasive Etiologic Diagnosis of Cardiac Amyloidosis Using 99m Tc-3,3-Diphosphono-1,2-Propanodicarboxylic Acid ScintigraphyJACC, 2005
- Genetic study of transthyretin amyloid neuropathies: carrier risks among French and Portuguese familiesJournal of Medical Genetics, 2003
- Genetic epidemiology of familial amyloidotic polyneuropathy (FAP)‐type I in Póvoa do Varzim and Vila do Conde (north of Portugal)American Journal of Medical Genetics, 1995
- CONTROL OF HEART-RATE IN HEALTHY YOUNG MENThe Lancet, 1967